Bar-Or Amit
Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4; Experimental Therapeutics Program, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4; Clinical Research Unit, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4.
Exp Neurol. 2014 Dec;262 Pt A:57-65. doi: 10.1016/j.expneurol.2014.06.005. Epub 2014 Jun 10.
Teriflunomide (Aubagio®) is a once-daily oral immunomodulatory disease modifying therapy (DMT) presently approved in several regions, including Europe, North America, Latin America and Australia, for the treatment of relapsing forms of multiple sclerosis (RMS; RRMS). The therapeutic mode of action of teriflunomide in MS continues to be investigated. This review summarizes the main efficacy and safety results of the clinical trial program leading to teriflunomide's approval, highlights a number of practical clinical considerations, and overviews its presumed therapeutic mode of action (MOA) based on pharmacokinetic and pharmacodynamic observations and the growing body of teriflunomide-related in vitro, pre-clinical (animal model), and in vivo human studies.
特立氟胺（奥巴捷®）是一种每日一次的口服免疫调节疾病改善疗法（DMT），目前在包括欧洲、北美、拉丁美洲和澳大利亚在内的多个地区被批准用于治疗复发型多发性硬化症（RMS；RRMS）。特立氟胺在多发性硬化症中的治疗作用方式仍在研究中。本综述总结了导致特立氟胺获批的临床试验项目的主要疗效和安全性结果，强调了一些实际的临床考虑因素，并基于药代动力学和药效学观察以及越来越多的与特立氟胺相关的体外、临床前（动物模型）和体内人体研究，概述了其假定的治疗作用方式（MOA）。
